Scott Gettinger

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

(2024)10.1158/1078-0432.c.7181344.v1

Top 100%

0DataRank

Top 100%0 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more

Papers

Driven by 21 papers — median percentile 0. Top paper: “Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial”.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30111-x

N/A

6.6DataRank · unranked

541 citations

Kurt A. Schalper, Scott Gettinger, Amit Mahajan, Roy S. Herbst, Anne C. Chiang +19 more

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209

N/A

3.1DataRank · unranked

105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

JCI Insight(2020)10.1172/jci.insight.129353

N/A

2.2DataRank · unranked

62 citations

Federica Costa, Rituparna Das, Alyssa Duffy, Mehmet Samur, Samuel S. McCachren +17 more

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

New England Journal of Medicine(2015)10.1056/nejmoa1507643

N/A

1.4DataRank · unranked

9414 citations

Luis Paz-Ares, Diane P Holder, David R. Spigel, Martin Steins, Neal E. Ready +38 more

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.10.001

N/A

0.617DataRank · unranked

60 citations

Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu +11 more

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0251

N/A

0.564DataRank · unranked

42 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more

Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-006921

N/A

0.553DataRank · unranked

39 citations

Jan Martínek, Bradley A. Krasnick, Yunjiang Zheng, Keenan J. Robbins, Rihao Qu +29 more

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.02.009

N/A

0.494DataRank · unranked

26 citations

Jieling Miao, Mihaela Cristea, Allen Chen, Jacob Sands, Roy H. Decker +13 more

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)

JCO Clinical Cancer Informatics(2023)10.1200/cci.22.00165

N/A

0.336DataRank · unranked

4 citations

Weijia Fan, Aijin Wang, Riha Vaidya, Mary W. Redman, Scott Gettinger +5 more

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad003

N/A

0.330DataRank · unranked

8 citations

Qian Lu, Mary W. Redman, Susan S. Tavernier, Lori M. Minasian, Ellen V. Sigal +17 more

Genetic determinants of EGFR -Driven Lung Cancer Growth and Therapeutic Response In Vivo

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.04.13.036921

N/A

0.243DataRank · unranked

3 citations

Chuan Li, Hongchen Cai, Jessica A. Hellyer, Wen-Yang Lin, Deborah Ayeni +15 more

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

European Journal of Cancer(2022)10.1016/s0959-8049(22)01023-1

N/A

0.104DataRank · unranked

1 citations

Zeyuan Song, Scott Gettinger, Edith P. Mitchell, JJ Wright, Jeff Moscow +14 more

Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9104

N/A

0.104DataRank · unranked

1 citations

Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu +7 more

Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9121

N/A

0.104DataRank · unranked

1 citations

Frederick H. Wilson, Sarah B. Goldberg, Anne C. Chiang, Brian S. Henick, Elin Rowen +10 more

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Journal for ImmunoTherapy of Cancer(2014)10.1186/2051-1426-2-s3-o7

N/A

0DataRank · unranked

0 citations

Rakesh Verma, Mario Sznol, Chandra Sekhar Boddupalli, Scott Gettinger, Harriet Kluger +3 more

Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9046

N/A

0DataRank · unranked

0 citations

Dzifa Y. Duose, Jiexin Zhang, Mary W. Redman, Rossana Lazcano Segura, Mario L. Marques‐Piubelli +14 more

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9044

N/A

0DataRank · unranked

0 citations

Hsin-Hui Huang, Mary W. Redman, Roy S. Herbst, Scott Gettinger, Lyudmila Bazhenova +15 more

Data from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

(2023)10.1158/1078-0432.c.6530444

N/A

0DataRank · unranked

0 citations

Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia B. Jilaveanu +17 more

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Cancer Research(2024)10.1158/0008-5472.can-23-0438

N/A

0DataRank · unranked

24 citations

Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu, Lok-Hei Chan, Jungmin Choi +15 more

Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

(2024)10.1158/1078-0432.c.7181344.v1

Top 100%

0DataRank

Top 100%0 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1385

N/A

0DataRank · unranked

122 citations

Chuan Li, Hongchen Cai, Jessica A. Hellyer, Wen-Yang Lin, Deborah Ayeni +15 more

Scott Gettinger

Indexed papers

Top data-sharing exemplar

Papers